Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Varian Medical Systems Bolsters Oncology Unit With Zmed Purchase

This article was originally published in The Gray Sheet

Executive Summary

Varian Medical System's acquisition of SonArray three-dimensional ultrasound technology will enable the firm to enhance its image-guided radiotherapy line for radiation oncology clinics

You may also be interested in...



Lehman Brothers Global Healthcare Conference In Brief

Gen-Probe pursues HPV assay: Human papillomavirus test technology access is being sought by the company, which has held discussions with "three or four" developers thus far about potential "ways to collaborate," CFO Herm Rosenman reported March 3 at the Lehman Brothers Global Healthcare Conference in South Beach, Florida. HPV market participants include Digene (DNAwithPap) and Roche (Amplicor). Should discussions be unsuccessful, Gen-Probe "will continue to engineer our own" intellectual property to work around current barriers to entering the market, according to Rosenman. Gen-Probe projects $235 mil.-$245 mil. in revenue this year, supported by strong sales of its Tigris automated nucleic acid test platform (1"The Gray Sheet" Jan. 5, 2004, p. 5)...

Lehman Brothers Global Healthcare Conference In Brief

Gen-Probe pursues HPV assay: Human papillomavirus test technology access is being sought by the company, which has held discussions with "three or four" developers thus far about potential "ways to collaborate," CFO Herm Rosenman reported March 3 at the Lehman Brothers Global Healthcare Conference in South Beach, Florida. HPV market participants include Digene (DNAwithPap) and Roche (Amplicor). Should discussions be unsuccessful, Gen-Probe "will continue to engineer our own" intellectual property to work around current barriers to entering the market, according to Rosenman. Gen-Probe projects $235 mil.-$245 mil. in revenue this year, supported by strong sales of its Tigris automated nucleic acid test platform (1"The Gray Sheet" Jan. 5, 2004, p. 5)...

Nomos Goes Public Via North American Scientific Merger Valued At $56 Mil.

Radiation oncology firm North American Scientific, Inc. (NASI) will more than triple its revenue to $55-$60 mil. with the purchase of intensity modulated radiation therapy (IMRT) developer Nomos under an Oct. 27 agreement

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel